Data completeness
0/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PITRESSIN TANNATE is a vasopressin tannate injection indicated for management of vasopressin-responsive conditions, primarily central diabetes insipidus and certain GI hemorrhage cases. It is a long-acting formulation of vasopressin, an antidiuretic hormone analog that works by binding to vasopressin receptors to increase water reabsorption in the kidney and promote vasoconstriction.
Pre-Launch
Early-stage commercial opportunity with small team building phase; career growth depends on successful launch execution and market adoption.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PITRESSIN TANNATE offers pre-launch career entry for professionals building a niche therapeutic franchise from inception. Working on this product provides visibility into early-stage commercialization, specialist market development, and hospital/endocrinology relationships with high-touch customer engagement.
Brand ManagerProduct Manager
Worked on PITRESSIN TANNATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.